N

ewly diagnosed lung cancer patients are half as likely to die of the disease if they take a Merck drug alongside standard chemotherapy, according to new trial data that eclipsed doctors’ expectations.

The trial, which compared a combination of chemo and Merck’s blockbuster Keytruda against chemo alone, found that patients in the combo group were 51 percent more likely to be alive after one year. Those getting Merck’s drug were also 48 percent less likely to have their cancer progress in the same period.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I had to stop the keytruda. I have developed hypothyroidism and within the last couple months acute renal failure as a result of taking this medication. Still on high-dose steroids to try to correct the condition without help or Improvement so far

    • So sorry to hear that. My husband himself just started keytruda along with pem traxade. His first dose went well and he actually said that he felt better then he normally does so we’re praying that this works he’s now on maintenance therapy and has been for two years we realize the devastating possible side effects but feel the benefits far outweigh the risk for now we will keep you in our prayers good luck and I hope the side effects can be reversed keep your faith in God he is the ultimate position our faith is what has gotten us this far God bless

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.